The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform
Laurent Fischer - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind multicenter phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis study Design of the Tandem trial
Contemporary Clinical Trials, 2020Co-Authors: Marcos Pedrosa, Star Seyedkazemi, Sven Francque, Arun J Sanyal, Mary E Rinella, Michael Charlton, Rohit Loomba, V Ratziu, Jossy Kochuparampil, Laurent FischerAbstract:Abstract Background Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways involved in NASH. Design Tandem (CLJC242A2201J; NCT03517540 ) is a 48-week, phase 2b, randomized, double-blind, multicenter study in 200 adult patients with biopsy-proven NASH and liver fibrosis. Patients will be randomized in a 1:1:1:1 ratio to receive either TXR 140 μg once daily (qd), CVC 150 mg qd, TXR 140 μg + CVC 150 mg qd, or TXR 90 μg + CVC 150 mg qd. The study comprises a 48-week treatment period and 4 weeks of follow-up. The key inclusion criterion is presence of NASH with fibrosis stage F2/F3 as seen on screening liver biopsy or on historical liver biopsy performed within 6 months prior to screening. Objectives The primary objective is evaluation of the safety and tolerability of combination therapy compared with the monotherapies over 48 weeks. The secondary objective is to evaluate efficacy as assessed by ≥1-point improvement in liver fibrosis versus baseline or resolution of steatohepatitis after 48 weeks. Summary Tandem will evaluate the combination of TXR and CVC with respect to safety and efficacy outcomes related to improvement in fibrosis or resolution of steatohepatitis. Given the effects of TXR and CVC in multiple pathophysiological pathways associated with NASH, combination therapy is likely to show additional benefits compared with monotherapy.
M. El-kosheiry - One of the best experts on this subject based on the ideXlab platform.
-
A simple method for amorphous Tandem solar cell suboptimal Design
Proceedings of MELECON '94. Mediterranean Electrotechnical Conference, 1994Co-Authors: M. El-kosheiryAbstract:A simple method is proposed to Design Tandem solar cells made from amorphous silicon alloys in a series-connected cell structure. The method is based on the criterion of photocurrent matching in the individual cells forming the Tandem structure. The algorithm does not involve detailed conversion efficiency calculations in each iteration and thereby offers a significant speed advantage compared to the previous Tandem cell calculations. As such, the method provides a quick estimate of sub-optimal Tandem Design.
Barbara K. Burton - One of the best experts on this subject based on the ideXlab platform.
-
Population-Based Newborn Screening for Mucopolysaccharidosis Type II in Illinois: The First Year Experience
The Journal of Pediatrics, 2019Co-Authors: Barbara K. Burton, George E. Hoganson, Julie Fleischer, Dorothy K. Grange, Stephen R. Braddock, Rachel Hickey, Lauren Hitchins, Daniel Groepper, Katherine M. Christensen, Amelia KirbyAbstract:Objectives To assess the outcome of population-based newborn screening for mucopolysaccharidosis type II (MPS II) during the first year of screening in Illinois. Study Design Tandem mass spectrometry was used to measure iduronate-2-sulfatase (I2S) activity in dried blood spot specimens obtained from 162 000 infant samples sent to the Newborn Screening Laboratory of the Illinois Department of Public Health in Chicago. Results One case of MPS II and 14 infants with pseudodeficiency for I2S were identified. Conclusions Newborn screening for MPS II by measurement of I2S enzyme activity was successfully integrated into the statewide newborn screening program in Illinois.
-
Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience
The Journal of Pediatrics, 2017Co-Authors: Barbara K. Burton, George E. Hoganson, Dorothy K. Grange, Stephen R. Braddock, Joel Charrow, Darrell J. Waggoner, Brad T. Tinkle, Michael Schneider, Claudia Nash, Heather ShryockAbstract:Objectives To assess the outcomes of newborn screening for 5 lysosomal storage disorders (LSDs) in the first cohort of infants tested in the state of Illinois. Study Design Tandem mass spectrometry was used to assay for the 5 LSD-associated enzymes in dried blood spot specimens obtained from 219 973 newborn samples sent to the Newborn Screening Laboratory of the Illinois Department of Public Health in Chicago. Results The total number of cases with a positive diagnosis and the incidence for each disorder were as follows: Fabry disease, n = 26 (1 in 8454, including the p.A143T variant); Pompe disease, n = 10 (1 in 21 979); Gaucher disease, n = 5 (1 in 43 959); mucopolysaccharidosis (MPS) type 1, n = 1 (1 in 219 793); and Niemann-Pick disease type A/B, n = 2 (1 in 109 897). Twenty-two infants had a positive screen for 1 of the 5 disorders but could not be classified as either affected or unaffected after follow-up testing, including genotyping. Pseudodeficiencies for alpha-L-iduronidase and alpha-glucosidase were detected more often than true deficiencies. Conclusions The incidences of Fabry disease and Pompe disease were significantly higher than published estimates, although most cases detected were predicted to be late onset. The incidences of Gaucher disease, MPS I, and Niemann-Pick disease were comparable with previously published estimates. A total of 16 infants could not be positively identified as either affected or unaffected. To validate the true risks and benefits of newborn screening for LSD, long term follow-up in these infants and those detected with later-onset disorders will be essential.
Denis Mencaraglia - One of the best experts on this subject based on the ideXlab platform.
-
III–V Solar Cells
arXiv: Materials Science, 2014Co-Authors: James P. Connolly, Denis MencaragliaAbstract:The III–V semiconductor materials provide a range of opto-electronic properties well suited to bandgap engineering and high efficiency solar cells. The Design process, III–V growth and fabrication methods are described for homogeneous and heterogeneous structures, and the magnitude of fundamental thermal and radiative losses for important III–V solar cell materials calculated. An analytical model is presented, analysing solar cell performance in detailed terms of processes in the space charge region and charge neutral layers of solar cells. The model formulates the solar cell radiative efficiency as a function of bias, providing a quantitative measure of how close devices come to the ideal efficiency limit. Single junction pin and record efficiency pn GaAs cells are analysed and their radiative efficiency quantified, concluding that radiatively dominated behaviour is reached in the more efficient np Design. Tandem and triple junction III–V concepts are reviewed and efficiency limits placed in the context of achievable Designs. Experimental data are modelled for both structures and the radiative efficiency quantified. The more radiatively efficient Tandem Design is found to be closer to its fundamental efficiency limit for a radiatively dominated dual junction structure, as a consequence of lower non-radiative recombination rates. The application of III–V materials to quantum confined structures is finally reviewed with specific regard to the quantum well solar cell and its demonstrated 90% radiative efficiency at high bias as a result of the lower bandgap undoped multiple quantum well region.
-
Chapter 7:III–V Solar Cells
Materials Challenges, 2014Co-Authors: James P. Connolly, Denis MencaragliaAbstract:The III–V semiconductor materials provide a range of opto-electronic properties well suited to bandgap engineering and high efficiency solar cells. The Design process, III–V growth and fabrication methods are described for homogeneous and heterogeneous structures, and the magnitude of fundamental thermal and radiative losses for important III–V solar cell materials calculated. An analytical model is presented, analysing solar cell performance in detailed terms of processes in the space charge region and charge neutral layers of solar cells. The model formulates the solar cell radiative efficiency as a function of bias, providing a quantitative measure of how close devices come to the ideal efficiency limit. Single junction pin and record efficiency pn GaAs cells are analysed and their radiative efficiency quantified, concluding that radiatively dominated behaviour is reached in the more efficient np Design. Tandem and triple junction III–V concepts are reviewed and efficiency limits placed in the context of achievable Designs. Experimental data are modelled for both structures and the radiative efficiency quantified. The more radiatively efficient Tandem Design is found to be closer to its fundamental efficiency limit for a radiatively dominated dual junction structure, as a consequence of lower non-radiative recombination rates. The application of III–V materials to quantum confined structures is finally reviewed with specific regard to the quantum well solar cell and its demonstrated 90% radiative efficiency at high bias as a result of the lower bandgap undoped multiple quantum well region.
Marcos Pedrosa - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind multicenter phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis study Design of the Tandem trial
Contemporary Clinical Trials, 2020Co-Authors: Marcos Pedrosa, Star Seyedkazemi, Sven Francque, Arun J Sanyal, Mary E Rinella, Michael Charlton, Rohit Loomba, V Ratziu, Jossy Kochuparampil, Laurent FischerAbstract:Abstract Background Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways involved in NASH. Design Tandem (CLJC242A2201J; NCT03517540 ) is a 48-week, phase 2b, randomized, double-blind, multicenter study in 200 adult patients with biopsy-proven NASH and liver fibrosis. Patients will be randomized in a 1:1:1:1 ratio to receive either TXR 140 μg once daily (qd), CVC 150 mg qd, TXR 140 μg + CVC 150 mg qd, or TXR 90 μg + CVC 150 mg qd. The study comprises a 48-week treatment period and 4 weeks of follow-up. The key inclusion criterion is presence of NASH with fibrosis stage F2/F3 as seen on screening liver biopsy or on historical liver biopsy performed within 6 months prior to screening. Objectives The primary objective is evaluation of the safety and tolerability of combination therapy compared with the monotherapies over 48 weeks. The secondary objective is to evaluate efficacy as assessed by ≥1-point improvement in liver fibrosis versus baseline or resolution of steatohepatitis after 48 weeks. Summary Tandem will evaluate the combination of TXR and CVC with respect to safety and efficacy outcomes related to improvement in fibrosis or resolution of steatohepatitis. Given the effects of TXR and CVC in multiple pathophysiological pathways associated with NASH, combination therapy is likely to show additional benefits compared with monotherapy.